Abstract 3842
Background
Metronomic approach represent a promising strategy for the chemotherapy of drug-resistant tumors, because it can reduce the effective doses and adverse effects of chemotherapeutics. In particular, metabolic blockers reduce energy supply for multi-drug resistance systems, thus increasing tumor cells’ reactivity to chemotherapeutics. Metformin is an anti-diabetic drug that blocks mitochondrial respiration, interferes with ATP production and with proliferation of cancer cells. However, the effect of drug-resistance of prostate cancer cells on their reactivity to metformin has not yet been evaluated.
Methods
Here, we analysed short- and long-term cytotoxic and pro-apoptotic effects of metformin on the phenotype of human prostate cancer PC-3 and DU145 cells and their docetaxel (DCX)-resistant lineages (PC-3-DCX20 and DU145_DCX20; obtained after long-term treatment with 20 nM DCX). We concentrated on their DCX-resistance pattern and compared their epithelial-mesenchymal transition (EMT)-related phenotype, invasive potential and the activity of ATP-binding cassette (ABC) transporters in the presence of metformin and/or DCX.
Results
Metformin increased the sensitivity of drug-resistant PC-3 and DU145 cells to DCX; even though PC-3_DCX20 cells displayed reduced sensitivity to combined metformin/DCX treatment. When administered alone, metformin exerted less prominent cytostatic effects on PC_DCX20 cells than on their DU145_DCX20 counterparts. This effect was accompanied by EMT-related morphological changes, accompanied by the up-regulation of connexin (Cx)43.
Conclusions
These data indicate that reactivity of drug-resistant prostate cancer cells to metformin may depend on the efficiency of metabolic stress-induced EMT. EMT-related metabolic elasticity that apparently increases invasive potential of PC3 cells in the absence of DCX may limit the application of metformin in therapy of drug-resistant prostate tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jagiellonian University, Faculty of Biochemistry, Biophysics and Biotechnology.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5877 - Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial
Presenter: Jonas Jarczyk
Session: Poster Display session 3
Resources:
Abstract
5204 - A differential bladder microbiota composition is associated with tumor grade in bladder cancer.
Presenter: Monica Parra-Grande
Session: Poster Display session 3
Resources:
Abstract
4904 - Molecular characterization of metastatic urothelial carcinoma (mUC) in prior or current smokers (PCS) vs non-smokers (NS)
Presenter: Victor Sacristan Santos
Session: Poster Display session 3
Resources:
Abstract
5370 - Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency Results based on multiple RNA extraction kits and mutation detection methods
Presenter: Veronika Weyerer
Session: Poster Display session 3
Resources:
Abstract
2579 - Title: Genomic characterization of non-schistosomiasis-related squamous cell carcinoma (NSR-SCC) of the urinary bladder: a retrospective study of potential prognostic and predictive biomarkers
Presenter: Esmail Al-ezzi
Session: Poster Display session 3
Resources:
Abstract
2203 - TiNivo: Tivozanib combined with nivolumab results in prolonged progression free survival in patients with metastatic renal cell carcinoma (mRCC). Final Results.
Presenter: Philippe Barthelemy
Session: Poster Display session 3
Resources:
Abstract
4712 - First-Line Pembrolizumab (pembro) Monotherapy for Advanced Non‒Clear Cell Renal Cell Carcinoma (nccRCC): Updated Follow-Up for KEYNOTE-427 Cohort B
Presenter: Cristina Suárez
Session: Poster Display session 3
Resources:
Abstract
2091 - First-Line Pembrolizumab (pembro) Monotherapy in Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Updated Follow-Up For KEYNOTE-427 Cohort A
Presenter: James Larkin
Session: Poster Display session 3
Resources:
Abstract
2368 - Association Between Depth of Response and Overall Survival: Exploratory Analysis in Patients With Previously Untreated Advanced Renal Cell Carcinoma (aRCC) in CheckMate 214
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
6008 - Quality of life in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214: updated results
Presenter: David Cella
Session: Poster Display session 3
Resources:
Abstract